NDA 208780 · Legacy
Esbriet
Pirfenidone · Oral · Pyridone
OrphanLast checked: Nov 20, 2026Latest source record: Feb 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jan 11, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
144
29 Phase 3, 18 recruiting
FAERS reports
40,844
22,668 serious, 9,477 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2025.
ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ( 1 )
Mechanism: The mechanism of action of pirfenidone in the treatment of IPF has not been established.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- ESBRIET · PIRFENIDONE 801MG · TABLET, ORAL · Prescription · TE AB
- ESBRIET · PIRFENIDONE 267MG · TABLET, ORAL · Prescription · TE AB
- ESBRIET · PIRFENIDONE 534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pirfenidone" as an intervention, any sponsor and status, largest first.
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
PureTechIndustry
NCT07284602 · 1,100 participants (planned) · Start Jun 26, 2026 · Primary completion Nov 2029
Drug: Deupirfenidone; Pirfenidone (PFD) · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Palm Spring, California; Redding, California; Hialeah, Florida · 18 sites in all
- Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00662038 · 1,058 participants · Start Aug 2008 · Primary completion Feb 2016
Drug: pirfenidone · For: Idiopathic Pulmonary Fibrosis
Sites: South San Francisco, California
- Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Assiut UniversityAcademic, hospital or other
NCT05842681 · 1,000 participants (planned) · Start Jun 1, 2023 · Primary completion Jan 1, 2027
Drug: Azithromycin; Methylprednisolone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Asyut, Egypt · 2 sites in all
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CarePivotal-lookingTerminated
Lakefront Biotherapeutics NVIndustry
NCT03733444 · 781 participants · Start Nov 5, 2018 · Primary completion Mar 30, 2021
Drug: GLPG1690; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 132 sites in all
- Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT01366209 · 555 participants · Start Jun 2011 · Primary completion Feb 2014
Drug: Pirfenidone; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Brisbane, California
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CarePivotal-lookingTerminated
Lakefront Biotherapeutics NVIndustry
NCT03711162 · 525 participants · Start Nov 28, 2018 · Primary completion Mar 30, 2021
Drug: GLPG1690; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 132 sites in all
- A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01872689 · 505 participants · Start Oct 13, 2013 · Primary completion Jul 28, 2017
Drug: Lebrikizumab; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 112 sites in all
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07082842 · 472 participants (planned) · Start Oct 27, 2025 · Primary completion Jan 15, 2031
Drug: HEC585; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death7,558
- nausea5,186
- fatigue3,826
- diarrhoea3,309
- decreased appetite3,307
- dyspnoea3,004
- weight decreased2,261
- dizziness2,207
- cough2,093
- rash2,048
- vomiting1,819
- pneumonia1,794
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 4 |
| 2010 | 15 |
| 2011 | 6 |
| 2012 | 13 |
| 2013 | 10 |
| 2014 | 123 |
| 2015 | 2,883 |
| 2016 | 4,177 |
| 2017 | 2,430 |
| 2018 | 4,311 |
| 2019 | 4,319 |
| 2020 | 5,096 |
| 2021 | 4,958 |
| 2022 | 4,745 |
| 2023 | 3,566 |
| 2024 | 1,930 |
| 2025 | 1,287 |
| 2026 | 971 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Esbriet (Pirfenidone)
2024 spending
$42.1M
Beneficiaries
719
4,228 claims
Per beneficiary
$58,615
$63.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $671,048,018 |
| 2021 | $662,208,170 |
| 2022 | $409,939,065 |
| 2023 | $93,415,756 |
| 2024 | $42,143,982 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE, Bradford WZ, Castro-Bernardini S, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, et al. · BMC Pulm Med 2021 · Comparative Study, Meta-Analysis
- Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
Raghu G, Richeldi L, Fernández Pérez ER, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, et al. · Lancet 2011 · Comparative Study, Multicenter Study
- Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS, Murray S, Yow E, et al. · Chest 2024 · Comparative Study, Randomized Controlled Trial
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.